N-Desethyloxybutynin

Summary

N-Desethyloxybutynin (CHEMBL3544785) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 6
• Chemistry: 329.4 Da · C20H27NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3544785
Name	N-Desethyloxybutynin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	133577
Molecular formula	C20H27NO3
Molecular weight	329.4
InChIKey	SNIBJKHIKIIGPR-UHFFFAOYSA-N

SMILES: CCNCC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O

IUPAC name: 4-(ethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate

Also known as: N-desethyloxybutynin, Nrx-101, NRX-101, NT-0502, NT0502, N-DESETHYLOXYBUTYNIN

Patent coverage: 35 distinct patent families (93 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2/PHASE3	3
PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07227103	PHASE2/PHASE3	NOT_YET_RECRUITING	A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression
NCT03395392	PHASE2/PHASE3	COMPLETED	NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
NCT03396068	PHASE3	UNKNOWN	NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
NCT03402152	PHASE2/PHASE3	COMPLETED	NRX101 Glx Biomarker Validation Study
NCT02974010	PHASE2	COMPLETED	Sequential Therapy for the Treatment of Severe Bipolar Depression.
NCT05779267	Not specified	AVAILABLE	NRX-101 Expanded Access

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).